Fox Chase Cancer Center News

Patients with metastatic colorectal cancer who were treated with a biweekly dose of trifluridine-tipiracil (TAS-102) saw similar treatment effectiveness and reduced toxicity compared with treatment using standard dosing schedules, according to a recent study in The Oncologist that was co-authored by a Fox Chase Cancer Center physician.

The process of DNA amplification, the increase in the number of copies of a gene, has long been known to play a role in cancer and other diseases. More recently, research has focused on regulating this process for therapeutic benefit. Now, scientists at Fox Chase Cancer Center have “connected the dots” with a new paper that reviews decades of research and DNA amplification discoveries.

Joseph Van Galen, MD, MS, Chief Fellow in the Hematology/Oncology Fellowship Program at Fox Chase Cancer Center, was honored today with the American Society of Clinical Oncology’s (ASCO) Conquer Cancer Young Investigator Award.

A new study from researchers at Fox Chase Cancer Center released today at the American Society of Clinical Oncology’s (ASCO) Annual Meeting demonstrates that a simple addition to the electronic medical record (EMR) system can assist fertility preservation efforts for young adult cancer patients.

Marital status significantly impacts survival rates for patients with colorectal cancer, according to a new study co-authored by a Fox Chase Cancer Center researcher that was presented today at the American Society of Clinical Oncology’s (ASCO) Annual Meeting. Married individuals were found to have better survival rates than single or separated and divorced or widowed individuals.

Talin is a protein that plays an important role in the immune system by activating integrins, receptors that help cells attach to one another. Now a new study by Fox Chase Cancer Center researchers shows how talin has distinct binding modes for two types of integrins that are important in blood cells. It also highlights how switching modes can enhance the integrins, potentially making them stronger.

Fox Chase Cancer Center is pleased to announce the hiring of John C. Ruckdeschel, MD, FACP, FCCP, as a Professor in the Department of Hematology/Oncology.

Fox Chase Cancer Center, part of the Temple Health, has received a five-year renewal of its prestigious Cancer Center Support Grant (CCSG) from the National Cancer Institute (NCI), reaffirming its designation as an NCI-designated Comprehensive Cancer Center—an elite status held by only 57 centers nationwide.